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IMPORTANCE Patients with cerebral venous thrombosis (CVT) are at risk of recurrent venous
thrombotic events (VTEs). Non–vitamin K oral anticoagulants have not been evaluated in
randomized controlled trials in CVT.
OBJECTIVE To compare the efficacy and safety of dabigatran etexilate with those of
dose-adjusted warfarin in preventing recurrent VTEs in patients who have experienced a CVT.
DESIGN, SETTING, AND PARTICIPANTS RE-SPECT CVT is an exploratory, prospective,
randomized (1:1), parallel-group, open-label, multicenter clinical trial with blinded end-point
adjudication (PROBE design). It was performed from December 21, 2016, to June 22, 2018,
with a follow-up of 25 weeks, at 51 tertiary sites in 9 countries (France, Germany, India, Italy,
the Netherlands, Poland, Portugal, Russia, and Spain). Adult consecutive patients with acute
CVT, who were stable after 5 to 15 days of treatment with parenteral heparin, were screened
for eligibility. Patients with CVT associated with central nervous system infection or major
trauma were excluded, but those with intracranial hemorrhage from index CVT were allowed
to participate. After exclusions, 120 patients were randomized. Data were analyzed following
the intention-to-treat approach.
INTERVENTIONS Dabigatran, 150 mg twice daily, or dose-adjusted warfarin for a treatment
period of 24 weeks.
MAIN OUTCOMES AND MEASURES Primary outcome was a composite of patients with a new
VTE (recurrent CVT, deep vein thrombosis of any limb, pulmonary embolism, and splanchnic
vein thrombosis) or major bleeding during the study period. Secondary outcomes were
cerebral venous recanalization and clinically relevant non–major bleeding events.
RESULTS In total, 120 patients with CVT were randomized to the 2 treatment groups (60 to
dabigatran and 60 to dose-adjusted warfarin). Of the randomized patients, the mean (SD)
age was 45.2 (13.8) years, and 66 (55.0%) were women. The mean (SD) duration of exposure
was 22.3 (6.16) weeks for the dabigatran group and 23.0 (5.20) weeks for the warfarin group.
No recurrent VTEs were observed. One (1.7%; 95% CI, 0.0-8.9) major bleeding event
(intestinal) was recorded in the dabigatran group, and 2 (3.3%; 95% CI, 0.4-11.5) (intracranial)
in the warfarin group. One additional patient (1.7; 95% CI, 0.0-8.9) in the warfarin group
experienced a clinically relevant non–major bleeding event. Recanalization occurred in 33
patients in the dabigatran group (60.0%; 95% CI, 45.9-73.0) and in 35 patients in the
warfarin group (67.3%; 95% CI, 52.9-79.7).
CONCLUSIONS AND RELEVANCE This trial found that patients who had CVT anticoagulated
with either dabigatran or warfarin had low risk of recurrent VTEs, and the risk of bleeding was
similar with both medications, suggesting that both dabigatran and warfarin may be safe and
effective for preventing recurrent VTEs in patients with CVT.
TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02913326
JAMA Neurol. 2019;76(12):1457-1465. doi:10.1001/jamaneurol.2019.2764
Published online September 3, 2019.
Supplemental content
Author Affiliations: Author
affiliations are listed at the end of this
article.
Group Information: The members of
the RE-SPECT CVT Study Group are
listed at the end of the article.
Corresponding Author: José M.
Ferro, MD, Faculdade de Medicina,
Universidade de Lisboa, Hospital
Santa Maria, Neurology, 6th Floor,




JAMA Neurology | Original Investigation
(Reprinted) 1457
Downloaded From: https://jamanetwork.com/ on 02/17/2021
C erebral venous thrombosis (CVT) is a type of strokecaused by thrombosis of the dural sinus and/or cere-bral veins. The prevalence of CVT in high-income
countries is 1.3 to 1.6 per 100 000 persons1,2 and is higher in
low- and middle-income countries.3
In acute-phase CVT, less than 5% of patients die and approxi-
mately 75% make a full recovery.4 Those who survive acute CVT
areatincreasedriskofrecurrentvenousthromboticevents(VTEs)
in the cerebral veins and dural sinuses, veins of the limbs, and
splanchnic veins, or pulmonary embolism (PE).4-6 In observa-
tional studies, the risk of recurrent CVT was 1.5 per 100 persons
per year and the risk of all VTEs was 2.0 to 4.1 per 100 persons
per year.5,6 Most recurrences seem to occur in the months after
the initial thrombotic event.5,6
The recommended practice for preventing VTE recur-
rence after CVT is anticoagulation using vitamin K antago-
nists for variable periods, depending on the inherent throm-
botic risk of each patient.7,8 This recommendation is based on
the extrapolation of findings on prevention of recurrent VTE
in deep vein thrombosis (DVT).
Direct non–vitamin K oral anticoagulants are changing the
practice of anticoagulation and have been used to prevent DVT
and PE.9 Dabigatran etexilate is a direct thrombin antagonist
that has been proven to be efficacious and to have a good safety
and tolerability profile when used for stroke prevention in pa-
tients with atrial fibrillation10 as well as when used for treat-
ment and prevention of recurrent DVT and PE.11
Dabigatran and other non–vitamin K oral anticoagulants
are occasionally used off-label in patients with CVT. Small case
series have been published that found promising safety and
efficacy results,12-16 but these studies lacked controls and ran-
domization. Because of the low quality of available evidence,
European guidelines8 do not currently recommend non–
vitamin K oral anticoagulants after CVT.
We conducted RE-SPECT CVT (A Clinical Trial Comparing
Efficacy and Safety of Dabigatran Etexilate With Warfarin in
Patients With Cerebral Venous and Dural Sinus Thrombosis),
an exploratory randomized clinical trial to evaluate the effi-
cacy and safety of dabigatran compared with dose-adjusted
warfarin in the prevention of recurrent VTE and CVT.
Methods
Study Design and Participants
RE-SPECT CVT is an exploratory, multicenter PROBE design (pro-
spective, randomized, parallel-group, open-label with blinded
evaluation of end points) clinical trial conducted at 51 sites in 9
countries(France,Germany,India,Italy,theNetherlands,Poland,
Portugal, Russia, and Spain) from December 21, 2016, to June 22,
2018. All participating sites were tertiary medical centers with
an interest in CVT. This trial was approved by the institutional
review board or ethics committee at each site and, where re-
quired, by the national ethics committees for clinical research.
Written informed consent was obtained from all participants be-
fore randomization. Patients who could not directly provide con-
sent could designate a legally authorized representative to sign
the consent form on their behalf. The rationale, design, and pro-
tocol of RE-SPECT CVT have been published previously17; the full
trial protocol is available in Supplement 1.
We recruited consecutive patients of either sex who were
between 18 and 79 years of age and had a diagnosis of CVT con-
firmed by magnetic resonance imaging (MRI) plus MR venog-
raphy, computed tomography (CT) plus CT venography, or in-
traarterial venography. Patients should have achieved clinical
stability after receiving acute CVT treatment as required.
Major exclusion criteria were the inability to swallow oral
medication, CVT associated with central nervous system in-
fection or major head trauma, planned surgical procedure for
CVT (eg, decompressive hemicraniectomy), life-threatening or
major bleeding18 in the previous 6 months other than intra-
cranial hemorrhage from the index CVT, need to continue pre-
vious treatment with an anticoagulant for an indication other
than CVT, current or recent (<6 months) malignancy, and cre-
atinine clearance level less than 30 mL/min (to convert to mL/
s/m2, multiply by 0.0167) (eAppendix 1 in Supplement 2).
Randomization and Masking
Patientswererandomized1:1throughanonlinetelephone-guided
response system to receive either dabigatran (150 mg twice daily)
or warfarin (dose adjusted to maintain an international normal-
ized ratio [INR] between 2.0 and 3.0). Randomization took place
5 to 15 days after the initial acute treatment with unfractionated
or low-molecular-weight heparin. Randomization was stratified
by presence or absence of intracranial hemorrhage at baseline
neuroimaging.Therandomizationlistwasgeneratedbythestudy
sponsor (Boehringer Ingelheim) using a validated system. The
randomization code remained unseen by the whole trial team
up to database lock. Because RE-SPECT CVT was an open-label
trial, treatment allocation was not concealed from the patients
and investigators.
Procedure
The trial consisted of 3 sequential periods: a screening period
of 5 to 15 days, a treatment period of 24 weeks, and a follow-up
period of 7 days (Figure 1). Screened patients could be en-
rolled into the trial (ie, signed informed consent) once they had
a confirmed diagnosis of CVT; met the inclusion and exclu-
sion criteria; and received treatment for the acute phase of CVT,
Key Points
Question Is dabigatran etexilate or dose-adjusted warfarin
efficacious and safe to use in preventing the recurrence of venous
thrombotic events among patients with cerebral venous
thrombosis?
Findings In this exploratory randomized, open-label clinical trial
of 120 patients with cerebral venous thrombosis, no recurrent
venous thrombotic events were observed in patients randomized
to either the dabigatran or warfarin treatment group; 1 major
bleeding event was recorded among users of dabigatran and 2
among users of warfarin.
Meaning This study suggests that both dabigatran and
dose-adjusted warfarin may be safe options to prevent recurrent
venous thrombotic events in patients with cerebral venous
thrombosis.
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including with initial parenteral anticoagulation (unfraction-
ated heparin or low-molecular-weight heparin) as recom-
mended by current guidelines.7,8,19 Endovascular treatment
was allowed. Randomization occurred 5 days after the start of
parenteral anticoagulation therapy if the patient was stable,
but it could be postponed until the patient was stable for up
to 15 days after the start of parenteral therapy. In the warfarin
group, parenteral therapy continued until an INR of 2.0 or
higher was achieved for 2 consecutive measurements; in the
dabigatran group, parenteral therapy was discontinued as soon
as the trial treatment was started.
At screening, neuroimaging from the time of diagnosis of
the CVT was used. At the end of trial treatment, recanaliza-
tion was assessed by MRI plus MR venography by using a trial-
specific MRI protocol (eAppendix 2 in Supplement 2). All neu-
roimaging data were reviewed by the adjudication committee,
blinded for clinical data and treatment group.
AflowchartofthestudyisdepictedineAppendix3inSupple-
ment 2. Follow-up visits at the clinic were targeted at days 29,
85, and 169 (end of treatment) after randomization. A further
safety follow-up visit was performed 7 to 14 days after the end
of treatment. The end-of-treatment visit included the modified
Rankin Scale20 and neuroimaging. For patients who discontin-
ued trial medication, the end-of-treatment visit was carried out
at the discontinuation visit. Those who discontinued trial medi-
cation early were followed up for survival and for adverse, new
thrombotic, and bleeding events until day 176 (25 weeks) after
randomization, unless they withdrew their informed consent.
After the end of treatment or early discontinuation of trial medi-
cation, whether a patient received further nontrial treatment was
at the discretion of the treating physician.
Interventions and Outcomes
The trial medication was provided by the sponsor and was ad-
ministered to patients on the day of randomization. Dabiga-
tran was dispensed in 150-mg capsules and taken twice daily.
Warfarin was dispensed in 1-mg, 3-mg, or 5-mg tablets and
taken once daily; individual doses were titrated as needed to
maintain a target INR of 2.0 to 3.0. For patients in the warfa-
rin group, the INR measurements were performed as neces-
sary for dose adjustment and maintenance, to obtain target INR
as quickly as possible. The INR measurements were per-
formed daily from the start of treatment until concomitant hep-
arin treatment was stopped and then at least once every 2
weeks for the first 3 months thereafter, followed by once a
month. More frequent INR measurements could be taken if
required.
The primary outcome was the composite of the number
of patients with major bleeding according to International
Society on Thrombosis and Haemostasis criteria,18 or VTE
(recurrent CVT, DVT of any limb, PE, or splanchnic vein
thrombosis21), at the end of the trial. Secondary efficacy out-
comes included the number of patients with each category of
VTE and cerebral venous recanalization, as measured by change
in the score of occluded cerebral veins and sinuses.5 Second-
ary safety outcomes were the number of patients with major
bleeding according to International Society on Thrombosis and
Haemostasis criteria; composite of the number of patients with
new intracranial hemorrhage or worsening of the hemor-
rhagic component of a baseline lesion22 (eAppendix 6 in
Supplement 2); number of patients with clinically relevant non–
major bleeding events; number of patients with major bleed-
ing according to International Society on Thrombosis and Hae-
mostasis criteria, or clinically relevant non–major bleeding
events; and number of patients with any bleeding event. All
components of the primary and secondary outcomes (except
for number of patients with any bleeding event) were adjudi-
cated in a blinded manner by an adjudication committee. Other
exploratory outcomes included functional outcome, as-
sessed by the modified Rankin Scale; VTE-associated mortal-
ity; and all-cause mortality (eAppendix 4 in Supplement 2).
An independent outcome adjudication committee (eAppen-
dix 5 in Supplement 2) performed the blinded adjudication of
outcomes.
Figure 1. RE-SPECT Cerebral Venous Thrombosis (CVT) Trial Design
Screening
Open-label randomized treatment period
of 24 wk from randomization
Dabigatran, 150 mg twice daily



















INR indicates international normalized ratio; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin. Adapted with permission from SAGE Publications, Ltd.17
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Statistical Analysis
Because RE-SPECT CVT was an exploratory trial, no formal
statistical hypothesis was tested. Based on expected recruit-
ment rates, we planned to randomize 120 patients. Planning
RE-SPECT CVT as a noninferiority trial with a preservation of
about 50% of the recurrent events would require more than
2000 patients because of the low recurrent event rate (ap-
proximately 3% at 6 months).5,17 All analyses of primary and
secondary outcomes were descriptive (number, frequency,
and 95% CI). The full analysis set was defined as all patients
randomized. They were analyzed in their allocated treat-
ment group following the intention-to-treat approach,
regardless of whether they took the study medication.
The primary outcome and secondary efficacy outcomes
were analyzed for the full observation period. The secondary
safety outcome analyses were based on all randomized pa-
tients who received at least 1 dose of study medication. Cere-
bral venous recanalization, as measured by the change in num-
ber of occluded cerebral veins and sinuses after up to 24 weeks,
was presented as no change or as worsened (if there was at least
1 new vein or sinus occluded) or improved (if there was at least
1 vein or sinus recanalyzed). Patients with missing or unana-
lyzable MRI scans at the end of treatment were excluded from
this analysis. All statistical analyses were performed using SAS,
version 9.4 (SAS Institute Inc).
Results
The first patient was enrolled on December 21, 2016, and the
last patient completed the trial on June 22, 2018. Consecu-
tive patients with CVT (n = 228) from 36 of the 51 invited
centers in 9 countries were assessed for eligibility. In total,
120 patients with CVT were randomized to the 2 treatment
groups (60 to dabigatran and 60 to dose-adjusted warfarin).
Each group comprised 33 women (55.0%) and 27 men
(45.0%), with a mean (SD) age of 45.2 (13.8) years. Table 1
shows the baseline characteristics of the patients enrolled in
the study.
All randomized patients received at least 1 dose of their al-
lotted medication. Eleven (9.2%) patients in total (7 [1.7%] in
the dabigatran group and 4 [6.7%] in the warfarin group) dis-
continued medication prematurely (before 24 weeks). Rea-
sons for discontinuation in the dabigatran group were enlarge-
ment of baseline intracranial hemorrhage in 1 patient (not
judged by the blinded adjudication committee as new intra-
cranial bleeding), intestinal hematoma in another patient, and
other adverse events in 5 patients (epigastric or abdominal dis-
comfort in 2; urticaria, thrombocytopenia, and elevated liver
enzymes in 1 each). Five of these patients received other an-
ticoagulants (vitamin K antagonists in 4; low-molecular-
weight heparin in 1) after discontinuing the trial treatment. Two
patients in the warfarin group decided not to continue in the
trial, with 1 stopping at the 3-day visit and the other at the
1-month visit. Two other patients in the warfarin group with-
drew from the trial: 1 did not reach therapeutic INR values even
with high medication doses, and the other left for unknown
reasons.
Altogether, 109 (90.8%) patients completed the treat-
ment period (53 [88.3%] in the dabigatran group and 56 [93.3%]
in the warfarin group). Vital status was available for all pa-
tients at 25 weeks (end of follow-up period) (Figure 2). The
mean (SD) duration of exposure was 22.3 (6.16) weeks for the
dabigatran group and 23.0 (5.20) weeks for the warfarin group.
The median adherence to dabigatran, determined by the count-
ing of capsules by site personnel, was 99.7%; all patients were
within the 80% to 120% interval ([number of capsules taken]/
[number of capsules expected to be taken] × 100%). For war-
farin, the overall mean time in therapeutic range was 66.1%.
Table 2 shows the distribution of the outcomes. No recur-
rent VTEs were observed in either treatment group. Of the 3
major bleeding events, 1 was intestinal bleeding in the dabi-
gatran group (1 [1.7%]; 95% CI, 0.0-8.9), and 2 were intracra-
nial (subdural) hemorrhages in the warfarin group (2 [3.3%];
95% CI, 0.4-11.5).
No clinically relevant non–major bleeding events oc-
curred among patients in the dabigatran group, and only 1 pa-
tient with (genitourinary) bleeding was observed in the war-
farin group (1 [1.7%]; 95% CI, 0.0-8.9). Any bleeding,
irrespective of its severity, occurred in 20% of patients, with
the same frequency in both treatment groups (dabigatran: 12
[20.0%]; 95% CI, 10.8-32.3 and warfarin: 12 [20.0%]; 95% CI,
10.8-32.3).
Cerebral venous recanalization, assessed as a change in the
score of occluded cerebral veins and sinuses between base-
line and end-of-treatment neuroimaging, could be evaluated
in 55 patients in the dabigatran group and 52 patients in the
warfarin group. No patient worsened, whereas 33 patients
(60.0%; 95% CI, 45.9-73.0) in the dabigatran group and 35
(67.3%; 95% CI, 52.9-79.7) in the warfarin group experienced
improvement.
Among the patients (20 in each treatment group) with in-
tracranial hemorrhage at baseline, no new major bleeding
events occurred for dabigatran, whereas 1 major bleeding (new
intracranial hemorrhage) event was recorded for warfarin (1
[5.3%]; 95% CI, 0.1-26.0). In the same patients, worsening of
the hemorrhagic component of a baseline intracranial lesion
was observed in 1 patient in the dabigatran group (1 [5.0%];
95% CI, 0.1-24.9).
Adverse events other than bleeding are listed in Table 3.
Epigastric or abdominal discomfort leading to study drug dis-
continuation was reported in 2 patients (3.3%) randomized to
the dabigatran treatment.
Discussion
We found no recurrent VTE during the RE-SPECT CVT trial. This
finding indicates that the risk of recurrent VTE in patients with
CVT who received regular anticoagulant therapy, with either
dabigatran or dose-adjusted warfarin, for 6 months was low.
Anticoagulant therapy for 6 months with either dabigatran or
dose-adjusted warfarin was associated with few major or clini-
cally relevant bleeding events, new intracranial hemor-
rhages, or enlargement of baseline hemorrhagic lesions. These
results are in line with evidence that dabigatran is at least
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noninferior in efficacy compared with warfarin in indica-
tions other than CVT, presenting fewer bleeding events, spe-
cifically intracranial hemorrhages.23 Previous observational
studies on VTE recurrence in patients with CVT did not sys-
tematically record or adjudicate major bleeding events.5,6,8
With the limitation of the small number of adjudicated major
bleeds and their wide CIs, the frequency of major bleeding
events in RE-SPECT CVT was comparable to that reported for
dabigatran, 150 mg, in DVT trials11 and lower than the fre-
quency observed in stroke prevention in atrial fibrillation
trials.10 For warfarin, in the current study, the frequency of ma-
jor bleeding was comparable to that observed in trials of stroke
prevention in atrial fibrillation.10 The patients with CVT in this
study were younger than patients with atrial fibrillation and
did not have clinical or neuroimaging evidence of small ves-
sel disease, and oral anticoagulation was given for only 24
weeks. These factors may explain the lower rate of major bleed-
ing (ie, intracranial hemorrhage) witnessed for dabigatran in
RE-SPECT CVT.
Compared with the warfarin group, the dabigatran group
had more patients who discontinued trial medication. The rea-
son for the discontinuation was mainly the digestive system
adverse effects of the drug.
RE-SPECT CVT, which compared dabigatran to dose-
adjusted warfarin, adds reliable evidence to available data








Male 27 (45.0) 27 (45.0)
Female 33 (55.0) 33 (55.0)
Age group, y
<30 7 (11.7) 8 (13.3)
30-39 16 (26.7) 10 (16.7)
40-49 19 (31.7) 21 (35.0)
50-59 9 (15.0) 10 (16.7)
≥60 9 (15.0) 11 (18.3)
Country
France 3 (5.0) 4 (6.7)
Germany 5 (8.3) 8 (13.3)
India 12 (20.0) 7 (11.7)
Italy 7 (11.7). 7 (11.7)
The Netherlands 5 (8.3) 4 (6.7)
Poland 3 (5.0) 7 (11.7)
Portugal 8 (13.3) 14 (23.3)
Russia 16 (26.7) 6 (10.0)
Spain 1 (1.7) 3 (5.0)
Diagnosis of CVT
MRI with MR venography 48 (80.0) 44 (73.0)
CT with CT venography 15 (25.0) 23 (38.3)
MRI with catheter angiography 3 (5.0) 3 (5.0)
CT with catheter angiography 5 (8.3) 3 (5.0)
Parenchymal lesion on diagnostic
neuroimaging
Any lesions 27 (45.0) 24 (40.0)
Nonhemorrhagic lesion 13 (21.7) 13 (21.7)
Hemorrhagic lesion 18 (30.0) 19 (31.7)
Sinuses involved
Superior sagittal sinus 27 (45.0) 25 (41.7)
Left lateral (sigmoid and/or
transverse) sinus
26 (43.3) 34 (567)
Right lateral (sigmoid and/or
transverse) sinus
34 (56.7) 30 (50.0)
Straight sinus 8 (13.3) 12 (20.0)
Deep venous system 8 (13.3) 6 (10.0)
Cortical veins 11 (18.3) 16 (26.7)
Cerebellar veins 0 2 (3.3)
Jugular vein 22 (36.7) 21 (35.0)
Cavernous sinus 1 (1.7) 3 (5.0)
Symptoms/signs
Coma (Glasgow Coma Scale score: <9) 0 0
Decreased alertness (Glasgow Coma
Scale score: 9-14)
3 (5.0) 3 (5.0)
Monoparesis/hemiparesis 12 (20.0) 11 (18.3)
Seizure 13 (21.7) 16 (26.7)
Headache 54 (90.0) 55 (91.7)
Mental status disorder 4 (6.7) 4 (6.7)
Aphasia 5 (8.3) 7 (11.7)
Visual loss 7 (11.7) 3 (5.0)
Papilloedema 10 (16.7) 4 (6.7)
Diplopia, oculomotor palsy 6 (10.0) 5 (8.3)
(continued)








Oral contraceptive use 18 (30.0) 19 (31.7)
BMI ≥25 to <30 16 (26.7) 25 (41.7)
BMI ≥30 14 (23.3) 15 (25.0)
Previous venous thromboembolism 6 (10.0) 9 (15.0)
Genetic thrombophilia 5 (8.3) 3 (5.0)
Infection (ear, nose, throat) 4 (6.7) 2 (3.3)
Surgery 3 (5.0) 2 (3.3)
Puerperium 3 (5.0) 1 (1.7)
Severe dehydration 1 (1.7) 1 (1.7)
Drugs with prothrombotic effect 2 (3.3) 0
Malignancy (>6 mo) 0 1 (1.7)




Mechanical precipitants 1 (1.7) 0
CVT risk score
0-2 51 (85.0) 52 (86.7)
≥3 9 (15.0) 8 (13.3)
NIHSS score
0 43 (71.7) 48 (80.0)
1-4 15 (25.0) 10 (16.7)
5-15 2 (3.3) 2 (3.3)
16-42 0 0
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided
by height in meters squared); CT, computed tomography; CVT, cerebral venous
thrombosis; MR, magnetic resonance; MRI, MR imaging; NIHSS, National
Institutes of Health Stroke Scale (score range for this sample: 0-13, indicating
mild to moderate).
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because it was controlled and randomized and had blinded ad-
judication of efficacy and safety outcomes. Adherence was ex-
cellent in the dabigatran group, and the time in therapeutic
range was good (>65%) for patients in the warfarin group. To
increase external validity, RE-SPECT CVT was performed in
Western and Eastern Europe, Russia, and India, because these
regions have epidemiologic variations in demography and the
risk factors for CVT as well as different systems and levels of
health care.
Limitations
RE-SPECT CVT has several limitations. It was an exploratory trial
with a small sample size. Owing to the low frequency of recur-
rent VTE after CVT,5,6 the study was not powered to detect sta-
tistically significant differences between the 2 treatment groups
for recurrent VTE. Assuming a preservation of 50% of the ben-
efit of warfarin, a noninferiority trial with a 3% VTE rate would
require approximately 2000 patients. Given the low incidence
of CVT, such a trial is unlikely to be feasible.
Open-label compared with double-blind, double-
dummy trials in anticoagulation have complementary strengths
and weaknesses. Double-blind trials unavoidably deviate from
routine clinical practice, and doing so limits their external
validity.24,25 Open-label design may influence postrandom-
ization management decisions, as well as outcome reporting
and evaluation, and is a potential source of bias. To decrease
the risk of such bias, we used the PROBE design. External evalu-
ators, who were blinded to treatment allocation, adjudicated
the outcome events on the basis of predefined criteria.
As is the case for all randomized clinical trials, the inclu-
sion and exclusion criteria induced sample selection bias. The
characteristics of the sample were, in general, expected in a
convenience sample of patients with CVT admitted to ter-
tiary centers. Because patients who could not swallow were
excluded, no comatose patients were included in the trial. We
also excluded patients with major trauma, central nervous sys-
tem infections, or active cancer as well as those requiring
hemicraniectomy. The allocated sample consisted of CVT
cases of mild to moderate severity, as demonstrated by the low
score on the National Institute of Health Stroke Scale (score
range for this sample: 0-13, indicating mild to moderate), CVT
risk scores,26 and modified Rankin Scale at 4 weeks or up to
24 weeks.
The frequency of recurrent VTEs in RE-SPECT CVT was
lower than anticipated.5,6 This low frequency may be attrib-
utable to the excellent treatment adherence and good INR con-
trol among patients. Alternative explanations are follow-up of
only 6 months, the effect of early parenteral heparin, and se-
lection bias leading to a low inclusion rate for patients at high
risk for recurrence. Severely affected patients, often bedrid-
den for long periods, have a higher risk of DVT of the limbs and
PE compared with those less severely affected. Active cancer
is also a risk factor for recurrent VTE; these patients were ex-
cluded from the trial. Older age, male sex, genetic thrombo-
philia, and myeloproliferative syndromes increase the risk of
recurrent VTE in patients with CVT.5,6 RE-SPECT CVT had no
cases of myeloproliferative neoplasm or acquired thrombo-
philia, and only 8 patients with confirmed genetic thrombo-
philia were enrolled. Those conditions were not an exclusion
criterion, except for active or recent cancer.
Conclusions
This study showed that the risk of recurrent VTE was low in
patients with CVT who received anticoagulant therapy with
Figure 2. Enrollment, Randomization, and Treatment
228 Patients assessed for eligibility
108 Excluded
4 With unconfirmed diagnosis
24 Had unspecified reasons
62 Did not meet eligibility criteria
18 Had other reasons
7 Excluded
1 Had worsening of CVT
1 Had major intestinal bleeding
5 Had other adverse events
4 Excluded
2 Lost to follow-up
2 Withdrew
120 Randomized
60 Randomized to dabigatran
treatment
60 Received intervention as
randomized (treated set)
60 Included in full analysis
53 Completed 24-wk treatment
60 Randomized to dose-adjusted
warfarin treatment
60 Received intervention as
randomized (treated set)
60 Included in full analysis
56 Completed 24-wk treatment
CVT indicates cerebral venous
thrombosis.
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Table 2. Primary and Secondary Outcomes
Outcomes
No. (%) [95% CI]
Dabigatran Etexilate (n = 60) Warfarin (n = 60)
Primary outcome
Major bleeding or venous thrombotic event (recurrent CVT, DVT of any limb,
pulmonary embolism, splanchnic vein thrombosis)
1 (1.7) [0.0-8.9] 2 (3.3) [0.4-11.5]
Secondary outcomes
All venous thrombotic events 0 [0.0-6.0] 0 [0.0-6.0]
Recanalization: score of occluded veins/sinusesa
Improved 33 (60.0) [45.9-73.0] 35 (67.0) [52.9-79.7]
No change 22 (40.0) [27.9-54.1] 17 (33.0) [20.3-47.1]
Secondary safety outcomes
Major bleeding event 1 (1.7) [0.0-8.9] 2 (3.3) [0.4-11.5]
Clinically relevant non–major bleeding event 0 [0.0-0.6] 1 (1.7) [0.0-8.9]
Major bleeding or clinically relevant non–major bleeding event 1 (1.7) [0.0-8.9] 3 (5.0) [1.0-13.9]
Any bleeding 12 (20.0) [10.8-32.3] 12 (20.0) [10.8-32.3]
New intracranial hemorrhage or worsening of the hemorrhagic component of a baseline lesionb 1 (1.8) [0.0-9.6] 2 (3.8) [0.5-13.0]
New intracranial hemorrhage 0 [0.0-6.4] 2 (3.8) [0.5-13.0]
Worsening of the hemorrhagic component of a baseline lesion 1 (1.8) [0.0-9.6] 0 [0.0-6.7]
Exploratory outcomes
Functional outcome (modified Rankin Scale)c
After 4 wk
0-1 51 (91.1) 52 (89.7)
2 5 (8.9) 5 (8.6)
3 0 1 (1.7)
>3 0 0
Up to 24 wk
0-1 54 (91.5) 53 (91.4)
2 4 (6.8) 3 (5.2)
3 0 2 (3.4)
>3 1 (1.7) 0
Venous thrombotic event–associated mortality 0 [0.0-6.0] 0 [0.0-6.0]
All-cause mortality 0 [0.0-6.0] 0 [0.0-6.0]
Abbreviations: CVT, cerebral venous thrombosis; DVT, deep vein thrombosis.
a Evaluated in 55 patients allocated to dabigatran and 52 to warfarin.
b Available for 56 patients in the dabigatran group and 53 in the warfarin group.
c Available for 56 patients in the dabigatran group and 58 in the warfarin group at 4 weeks, and for 59 patients in the dabigatran group and 58 in the warfarin group
up to 24 weeks.
Table 3. Patients With Adverse Events
Variable
No. (%)
Dabigatran Etexilate (n = 60) Warfarin (n = 60)
Any adverse event 47 (78.3) 42 (70.0)
Serious adverse event 8 (13.3) 6 (10.0)
Adverse event leading to trial drug discontinuation 7 (11.7) 0
Worsening of the index CVT 1 (1.7) NA
Intestinal hematoma, major bleeding event 1 (1.7) NA
Epigastric/abdominal discomfort 2 (3.3) NA
Urticaria 1 (1.7) NA
Thrombocytopenia 1 (1.7) NA
Elevated liver enzymes 1 (1.7) NA
Adverse event occurring in ≥5 patients, system organ class/preferred terma
Headache 10 (16.7) 8 (13.3)
Depression 2 (3.3) 4 (6.7)
Abdominal pain/epigastric discomfort 4 (6.7) 2 (3.3)
Diarrhea 4 (6.7) 2 (3.3)
Cough 5 (8.3) 0
Abbreviations: CVT, cerebral venous thrombosis; NA, not applicable.
a Bleeding not listed (see Table 2).
Safety and Efficacy of Dabigatran vs Warfarin After CVT Original Investigation Research
jamaneurology.com (Reprinted) JAMA Neurology December 2019 Volume 76, Number 12 1463
Downloaded From: https://jamanetwork.com/ on 02/17/2021
either dabigatran or dose-adjusted warfarin for 6 months.
Anticoagulant therapy was associated with few major or clini-
cally relevant bleeding events, new intracranial bleeds, or en-
largement of baseline hemorrhagic lesions. Dabigatran and
dose-adjusted warfarin may be safe options to prevent recur-
rent VTEs in patients with CVT. Because of the limited sample
size, we could not demonstrate the noninferiority or superi-
ority of either treatment.
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